entertainment -WSS

entertainment

author：fashion 2025-09-06 04:41:11 - browse：4233

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Infant mortality in U.S. rose last year for first time in decades: CDC

WSS

Coloradans with cystic fibrosis could lose access to Trikafta

A new drug could help frostbite victims avoid its ravages

Medicare must police algorithms in Medicare Advantage, Dems say

Elevance, SCAN deals highlight health insurer acquisition scrutiny

How to convince healthy people to buy insurance

How to convince healthy people to buy insurance

hotspot

entertainment

Wikipedia

Heart attack and stroke risk calculators need revising

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Duchenne breakthrough therapy leaves behind pioneering families

Bill would allow buprenorphine prescription for addiction via telehealth

Alkermes shareholders re

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

What does generative AI mean for health care? We asked experts

How neuroscience research could help beat back brain cancer

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Wikipedia

As AI regulations shape up, health tech startups beg for clarity

Ukraine seeks to reclaim its role as a hub for clinical trials

Bill would allow buprenorphine prescription for addiction via telehealth

New study raises questions about niacin and heart health

Life sciences investors close nearly $6 billion in new funds

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

focus

focus

hotspot